Tag: release

Daix (France), New York City (New York, États-Unis), le 9 juillet 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd'hui une transition au sein de son équipe de direction avec la nomination de Jason Campagna, MD, PhD, en tant que Président de la Recherche et du Développement (« R&D ») et Directeur Médical (« CMO »), ainsi que Martine Zimmermann, PharmD, en tant que Vice-Présidente Exécutive (« EVP ») en charge des affaires réglementaires et de l’ assurance qualité.

SAN FRANCISCO, July 09, 2025 (GLOBE NEWSWIRE) -- Allbirds, Inc. (Nasdaq: BIRD) today announced that it has signed three new distribution agreements for multiple countries throughout Eurasia as part of the Company’s strategy to build long-term scalable growth in overseas markets.

Daix (France), New York City (New York, United States), July 9, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced a leadership transition with the appointment of Jason Campagna, MD, PhD, as President of Research and Development (“R&D”) and Chief Medical Officer (“CMO”) and Martine Zimmermann, PharmD, as Executive Vice President (“EVP”) of Regulatory Affairs and Quality Assurance.

SAN FRANCISCO, July 09, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 32,350 shares of the Company’s common stock to two new employees (the “Inducement Grants”) on July 2, 2025 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).

LIVERMORE, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- FormFactor, Inc. (Nasdaq: FORM) will report financial results for its 2025 fiscal second quarter on Wednesday, July 30^th, 2025, at 1:25 p.m. Pacific Time. The public is invited to listen to a live webcast of FormFactor's conference call on the Investors section of the company's web site at www.formfactor.com.

Jersey City, NJ, July 09, 2025 (GLOBE NEWSWIRE) -- Amid the dizzying digital technology, decentralized finance, cryptocurrency and other trends shaping modern wealth creation, cryptocurrency is a staple of wealth creation today. There has never been more discussion or interest in cryptocurrency, whether in finance company holdings, institutional investors' portfolios, or retail investors' forex accounts. Meanwhile, in the midst of this discussion, one name is emerging as a leader in the cacophony - BAY miner. 

New York, July 09, 2025 (GLOBE NEWSWIRE) -- PaladinMining, a global provider of sustainable cloud mining infrastructure, has released a public statement commenting on the broader implications of recent international digital policy initiatives—particularly those centered around renewable energy integration and high-performance computing infrastructure.